Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
GlaxoSmithKline
Eli Lilly and Company
Three patients will be accrued at each of 5 dose levels. Dose escalation will only proceed if none of the additional 3 patients experience DLT. The highest dose level that generates DLT in 0/3 or 1/6 patients will be the maximum tolerated dose (MTD) or the doses recommended for subsequent studies. A total of 10 patients will be treated at the MTD to further assess the toxicity of the dosing regimen and its suitability for use in subsequent trials. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered. Treatment cycles will be repeated every 21 days. The protocol is also designed to enroll an additional 10 patients at the maximum tolerated dose to increase the confidence in the safety and suitability of the doses that are chosen for subsequent studies.
* Topotecan Day 1 and 8
* Pemetrexed Day 1
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven advanced solid tumors
Measurable or evaluable disease
Age ≥ 18 years
Karnofsky performance status ≥ 80% (ECOG 0 or 1)
Adequate liver, bone marrow and kidney function
You may not be if
More than 3 prior chemotherapy regimens in the metastatic setting
Prior treatment with topotecan or pemetrexed
Clinically significant third space fluid present at the time of treatment
Unable to interrupt aspirin, other non-steroidal anti-inflammatory drugs
Inability to take steroid premedications or vitamin supplementation
The presence of active brain metastases
Prior radiotherapy within 4 weeks prior to the first day of treatment
Prior surgery within 3 weeks prior to the first day of treatment
Prior chemotherapy within 3 weeks prior to the first day of treatment
